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This study provides background levels for five arsenic species in urine,
based on urinary data obtained from 95 nonoccupationally exposed
volunteers based in the UK. Using a novel, sensitive, robust and reliable
speciation methodology, five species of arsenic (arsenobetaine [AB],
arsenite [As31], arsenate [As51], monomethylarsonic acid [MMA51]
and dimethylarsinic acid [DMA51]) were determined in urine samples
collected from 95 adults. The analytical instrumentation used to analyze
the urine samples was a hyphenated micro liquid chromatography
(mLC) system coupled to an inductively coupled plasma mass spectrom-
etry (ICP-MS). Separation was achieved using an anion exchange
micro-sized column. The results presented give the 95th percentile of
concentrations, both uncorrected for creatinine (mg/L) and creatinine
corrected (mmol/mol) in urine for the 95 volunteers. Statistical analysis
was performed on the dataset using a Bayesian model to determine
and quantify effects of gender, smoking and diet. The statistical results
show that the consumption of fish, shellfish and red wine has a signifi-
cant elevating effect on AB, DMA and MMA urinary concentrations;
however, no significant effect was observed for smoking. The regres-
sion model results indicate that creatinine correction was effective for
arsenic species As31, MMA, DMA and AB. The background levels
established here can be used as reference values to help aid interpret-
ation of arsenic speciation results and better assess exposure.
Introduction
The International Agency for Research on Cancer (IARC) has
classified inorganic arsenic as a Group 1 agent, defined as car-
cinogenic to humans (1). Thus, it is imperative that exposure be
adequately controlled. Biological monitoring assesses whether a
person has been exposed to a substance or its metabolites, as it
encompasses all routes of potential exposure. Inorganic arsenic
exists as arsenite (trivalent, As3þ) and arsenate (pentavalent,
As5þ). When humans are exposed to inorganic arsenic, the
arsenic is reduced and methylated in the body to produce a
range of organic arsenic species, including dimethylarsinic acid
(DMA5þ) and monomethylarsonic acid (MMA5þ) (2). Pentavalent
methylated species are considered relatively nontoxic, since it is
thought that they cannot bind with molecules in the body (3). In
the UK, the most common route of exposure to arsenic is from
dietary sources. Dietary species of arsenic known as tetra alkylar-
sonium compounds include arsenobetaine (AB), arsenocholine
and trimethylarsine oxide, and are thought to be nontoxic (4).
The dietary sources of these species of arsenic include seafood,
shellfish, poultry and rice (4–8), and following ingestion, they are
eliminated in the urine unchanged (4).
Urine is the main excretory pathway for elimination of arsenic
from the body, in the general proportion 10–30% of inorganic
arsenic, 10–20% of MMA5þ and 60–80% of DMA5þ are eliminated
primarily via this route after inorganic exposure (2). The ease and
noninvasive sample collection makes it the biological sample of
choice in most studies, although determination of arsenic levels in
blood (9, 10) and serum (11) has been reported.
Currently, there are no unexposed background reference
values or exposed UK guidance values for any individual arsenic
species in urine. The US biological exposure index (BEI) (12)
and the German biological tolerance value (BAT) (13) are 35 and
50 mg/L, respectively, which are based on the summation of in-
organic arsenic and its metabolites, but not including AB. This is
a controversial, less well-understood area, because there seems
to be increasing numbers of foodstuffs containing other arsenic
compounds, e.g., DMA (6, 7), and therefore, exposure to arsenic
compounds either from environmental or from occupational
sources could be overestimated. The BEI and BAT approach of the
sum of the species less AB is an attempt to correct for dietary ex-
posure, but does not account for dietary DMA, MMA and arsenosu-
gars. To better assess environmental and occupational exposure,
arsenic speciation must be undertaken as a routine assay.
There are several population studies from around the world
that have reported urinary arsenic concentrations in unexposed
individuals. The two most comprehensive are the National Health
and Nutrition Examination Survey (NHANES) (14) in the USA,
where 2557 participants’ urine samples were measured for seven
species of arsenic, and the Human Biomonitoring of Environmental
Chemicals in Canada (HBECC) (15), where 6400 participants’
urine samples were measured for six species of arsenic. In addition,
similar national surveys have been conducted in France (n¼ 2102
participants) (16) and Korea (n¼ 5087 participants) (17).
However, both these studies used a total inorganic arsenic and the
metabolites minus AB technique to measure arsenic (16, 17). There
is also urinary arsenic speciation data for unexposed individuals in
smaller scale clinical studies from around the world such as
Germany (18), UK (19, 20), Italy (21) and Spain (22).
It is generally accepted that urinary arsenic speciation provides
the most coherent and detailed picture of exposure to arsenic
species and compounds. However, there is still a lack of established
reference values to usewhen trying to assess exposure to individual
species. By improving and modifying a novel micro liquid chroma-
tography (mLC)–inductively coupled plasma mass spectrometry
(ICP-MS) speciation method, previously developed at the Health
and Safety Laboratory (20) to have greater sensitivity and lower
limits of quantification (LOQs), this paper aims to provide reference
background values of five arsenic species in the urine of unexposed
individuals from a cohort of UK samples. Information on diet and
lifestyle was collected by questionnaire, as exposure to arsenic can
occur through diet and environmental sources. Such data will
provide a valuable contribution to the knowledge in this area.
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Separation was achieved using a hyphenated mLC system with an
ICP-MS (XSERIES 2, Thermo Fisher Scientific, Hemel Hempstead,
UK). The separation of arsenic species As3þ, As5þ, MMA5þ,
DMA5þ and AB was achieved using a 5-cm anion exchange guard
column (Dionex AG7 4 mm  50 mm i.d., Thermo Fisher
Scientific). The micro-flow delivery of sample and mobile phase
was accomplished using an ESI OneFAST system (Elemental
Scientific, Warrington, UK), which consists of a six port switch-
ing value and a 1-mL sample loop. The delivery of mobile phase
and sample onto the column was controlled by the ICP-MS peri-
staltic pump at a constant rate of 0.2 mL/min. The ICP-MS was
operated in a collision cell mode using 7% hydrogen in helium
(3.5 mL/min). The ICP-MS conditions were optimized using a
10-mg/L tuning solution containing arsenic, cobalt, indium and
uranium [made in 1% (v/v) nitric acid from 1000 mg/L stock
standards (ICP-MS standards, BDH, Poole, UK)].
Reagents
Arsenic speciation compounds sodium arsenite (NaAsO2),
sodium arsenate (Na2HAsO4.7H2O) and sodium cacodylate
(DMA; Na(CH3)2AsO2.3H2O) were all purchased from Fisher
Scientific (Loughborough, UK). Disodium methyl arsenate (99%
MMA; CH3AsO(OH)2) was purchased from ChemService (West
Chester, PA, USA). AB (C5H11AsO2) was purchased from
Sigma-Aldrich (Dorset, UK). Single standard stock solutions of
1000 mg/L were prepared in 1% (v/v) nitric acid (Romil,
Cambridge, UK) of As3þ, As5þ, MMA, DMA and AB in plastic volu-
metrics. All stock solutions were stored at 48C. The separation of
five arsenic species used a mobile phase of ammonium carbon-
ate purchased from VWR (Leicestershire, UK). Two mobile
phases were prepared daily by dissolving ammonium carbonate
in ultrapure deionized water (18.2 MVhm cm) from a Millipore
system (Merck Millipore, Billerica, MA, USA) to make 2 mM
(mobile Phase A) and 70 mM (mobile Phase B) solutions.
A 1-mg/L mixed species solution of all the five species was
prepared in 1% (v/v) nitric acid from the individual 1000-mg/L
single standard stock solutions on a weekly basis. Using the
1-mg/L mixed species solution standards of 0.5, 1, 2, 5, 10 and
20 mg/L were prepared daily in 2 mM of ammonium carbonate
(mobile Phase A).
Study group and sample collection
The volunteers in this study (n ¼ 95) consisted of 53 males and
42 females who were not occupationally exposed to arsenic. All
volunteers were over the age of 18 years, with the mean age of
people in this study 41.1 years. Individuals volunteered in re-
sponse to an email outlining the study sent to everyone at the
Health and Safety Laboratory (HSL), UK, and the Biomedical
Research Centre, Sheffield Hallam University, Sheffield, UK.
Participating volunteers were provided with informed consent,
as granted by the NRES Committee East Midlands–Leicester,
REC number 12/EM/0314. Volunteer information was collected
via a questionnaire, which was returned by post with the urine
sample. The information collected included: gender, age,
smoking habits and diet including vitamin and supplement use
in the previous 7 days. All urine samples were collected in 25 mL
urine collection bottles (Sterilin Ltd., Newport, UK) and sent to
the HSL by first class post. All urine samples had creatinine
content analyzed upon arrival and were then kept frozen at
2808C until analysis.
Sample preparation and analysis
Urine samples were thawed and mixed on a roller mixer before
analysis. Samples were diluted 1 in 15 with 2 mM ammonium
carbonate solution. All samples were analyzed in duplicate.
The certified reference materials (CRMs) used were Clinchek
urine control for arsenic species Level 1 and 2 (Lot 923) (Recipe,
Munich, Germany). In addition, a blank urine and spiked urine
sample (blank urine with all the five species of arsenic added at a
concentration of 10 mg/L) was analyzed at the beginning and the
end of each series of analyses and after every 10 samples. External
quality assurance for four of the arsenic species (not AB) was
undertaken in November 2012 by participation in the G-EQAS
(Friedrich-Alexander-University, Erlangen-Nuremberg, Germany)
trace element quality schemes.
Urinary creatinine concentrations were determined on all urine
samples by the Jaffe alkaline picrate method (23) on a Cobas Mira
Plus (Horiba Diagnostics, Northampton, UK). Creatinine (a break-
down product of creatine phosphate in muscle, and is usually pro-
duced at a fairly constant rate by the body) allows a urine sample
to be normalized for dilution or concentration. In determining the
creatinine levels using mathematical modeling, it was possible to
investigate the effectiveness of this correction for each arsenic
species.
Statistical analysis
The relationship was modeled between urinary concentration
and several factors (including gender, smoking and dietary
habits) using a multiple regression model. The Bayesian regres-
sion model used in this study had the form
1n(Asi)¼mþb11n(creatininei)þb2I ðsmokingiÞþb3I ðgenderiÞ
þb4I ðsupplementsiÞþb5I ðfishiÞþb6I ðshellfishiÞ
þb7I ðseaweediÞþb8I ðriceiÞþb9I ðmushroomsiÞ
þb10I ðredwineiÞb11I ðrealaleiÞþb12I ðpoultryiÞ
þb13I ðricemilkiÞb14I ðbraniÞþ1i
where Asi is the urinary concentration of arsenic on the ith indi-
vidual; m, the mean concentration (on the log scale) of a non-
smoking female who has not taken dietary substances
represented in the model; creatininei, the creatinine concentra-
tion with associated effect b1; I(smokeri) ¼ 0, if sample was from
a nonsmoker and 1 if smoker (b2 represents the smoking adjust-
ment to the mean concentration); I(genderi) ¼ 0, if the urine
sample was from a female and 1, if male (b3 represents the male
adjustment). Indicator variables and adjustments for the intake of
supplements, fish, shellfish, seaweed, rice, mushrooms, red wine,
real ale, poultry, rice milk and bran are similarly represented. 1i
are normally distributed residual errors with mean zero and stand-
ard deviation s.
One of the difficulties in analyzing urinary data is that mea-
surements are often below the LOQ (referred to as nondetects).
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However, it is known that these measurements lie between zero
and the LOQ, i.e., they are left censored. The data were modeled
using Markov Chain Monte Carlo (MCMC) methods in WinBUGs




The method described in this study is a sensitive, robust and re-
producible method for the routine determination of five species
of arsenic in a urine sample. The chromatograms in Figure 1
show that this optimized speciation method achieves full separ-
ation in ,6 min. The calibration range was 0–20 mg/L for all the
five species of arsenic. The limit of detection (LOD) was calcu-
lated as three times the standard deviation of the blank; this was
between 0.003 and 0.051 mg/L for all the five species of arsenic.
The LOQ for undiluted urine was calculated as 15 times the
mean background equivalent concentration (BEC) for all the five
species of arsenic. The BEC, LOD and LOQ for each arsenic
species are summarized in Table I. Of the 95 volunteer urine
samples measured, no level was below the LOQ for DMA and
only 1% of AB, 2% of MMA and 12% of As3þ were less than the
LOQ. However, 63% of the As5þ values were less than the LOQ of
0.04 mg/L
Analytical validation
The results for the in-house spiked urine quality control sample
shown in Table II gave an average recovery of 93% for As5þ,
MMA, DMA and AB and 90% for As3þ in the daily spiked urine
samples (n ¼ 29). The external quality assurance and CRMs ana-
lyzed are presented in Table II. Clinchek Levels 1 and 2 are certi-
fied for arsenic species; analyses gave good results for arsenic
species As5þ, MMA, DMA and AB, which were all within target
range, whereas As3þ did not show good agreement and gave a
result below the target range. However, the method is continual-
ly validated through participation in the German External
Quality Assessment Scheme (GEQAS); the results for the 50th
GEQAS in November 2012 being shown in Table II. The results
were within the target criteria for all the five species of arsenic.
This may suggest possible instability of As3þ in the Clinchek
CRMs.
Figure 1. Chromatograms showing full separation of five arsenic species in ,6 min using an ESI OneFAST system coupled to a 5-cm Dionex AG7 anion exchange column, with
mobile phases 2 and 70 mM of ammonium carbonate solution. (A) Overlay of the individual standard calibration chromatograms of 0–20 mg/L calibration. (B) CRM Clinchek 1 for
arsenic species in urine. (C) A urine sample of an unexposed individual adult.
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Of the 95 volunteers who participated, 82 were nonsmokers (33
females and 49 males) and 13 were smokers (9 females and 4
males). The urine results are summarized in Table III; the
median and the 95th percentile concentrations are expressed
both uncorrected for creatinine (mg/L) and creatinine corrected
(mmol/mol) in urine to adjust for urinary dilution. Creatinine
concentration ranged between 0.89 and 26.45 mmol/L. Nine
individuals had a low (below 3 mmol/L) or high (above
30 mmol/L) creatinine; however, creatinine concentration was
not an exclusion criterion (the reason being that excluding
these individuals would exclude a much higher proportion of
females than males). As 63% of As5þ measurements were below
the LOQ, the median As5þ concentration could not be quanti-
fied. The 95th percentiles for As3þ and As5þ were 0.54 (0.99
mmol/mol creatinine) and 0.23 mg/L (0.35 mmol/mol creatin-
ine), respectively. MMA, DMA and AB gave 95th percentiles of
2.37 (3.08 mmol/mol creatinine), 12.68 (16.08 mmol/mol cre-
atinine) and 126.7 mg/L (174.7 mmol/mol creatinine), respect-
ively. The median and 95th percentile concentrations for male
and female urinary arsenic species are also presented in
Table III. Females were observed to have lower median and 95th
percentiles of uncorrected for creatinine (mg/L) concentrations
for arsenic species As3þ, As5þ and MMA. However, for the
creatinine-corrected data, females show a lower median concen-
tration than males, but a higher 95th percentile for As3þ.
Statistical results
General statistical analysis using Prism Graphpad version 4 for
Windows was performed, comparing each arsenic species in re-
lation to gender and smoking habits. Using a two-tailed Mann–
Whitney nonparametric statistical test, there was no significant
difference between smokers and nonsmokers for inorganic
arsenic. Furthermore, no significant difference was found
between females and males for As3þ, As5þ, MMA or AB; however,
a statistically significant higher value for DMA was found in
females in the creatinine-corrected values only. The most likely
reason for this could be that women tend to have lower creatin-
ine levels than men (23), resulting in a higher corrected DMA
value for women than for men.
The Bayesian regression model was fitted separately for As3þ,
MMA, DMA and AB; however, due to the large proportion (63%)
of As5þ measurements below the LOQ, the analysis was not
carried out for As5þ. When the model was fitted to the data, a
creatinine coefficient of one was highly plausible for As3þ, MMA,
DMA and AB (i.e., the credible interval for the parameter b1 for
each of these species included unity). This indicated that a cre-
atinine correction may be effective for these species. The model
was subsequently refitted to the data with b1 set to unity, which
corresponds to fitting a regression model to creatinine-
corrected concentrations. The model considered all the vari-
ables including gender, smoking and dietary factors. Variables
that were considered to be nonsignificant at the 5% level were
subsequently removed from the model.
Table I
The background equivalent concentration (calibration curve intercept), LOD (signal-to-background
noise) and limit of quantification for all the five species of arsenic in mg/L, in addition to the













As3þ 0.001 0.004 0.02 11 12
As5þ 0.003 0.051 0.04 60 63
MMA 0.002 0.030 0.04 2 2
DMA 0.003 0.003 0.04 0 0
AB 0.002 0.003 0.03 1 1
Table III
Statistical summary of median and 95th percentile concentrations for all the five species of arsenic in both mg/L and mmol/mol creatinine, for both total urine samples and female and male urine samples
As3þ As5þ MMA DMA AB
mg/L mmol/mol creatinine mg/L mmol/mol creatinine mg/L mmol/mol creatinine mg/L mmol/mol creatinine mg/L mmol/mol creatinine
Total: n ¼ 95
Median 0.11 0.19 ,LOQ ,LOQ 0.56 0.90 2.44 4.30 3.87 10.0
95th Percentile 0.54 0.99 0.23 0.35 2.37 3.08 12.68 16.08 126.7 174.7
Females: n ¼ 42
Median 0.07 0.15 ,LOQ ,LOQ 0.48 0.95 2.43 5.35 6.77 19.4
95th percentile 0.44 1.05 0.15 0.38 2.10 3.42 12.68 26.7 333.9 672.8
Male: n ¼ 53
Median 0.15 0.22 ,LOQ ,LOQ 0.57 0.90 2.44 4.10 3.42 6.10
95th percentile 0.6 0.97 0.31 0.97 2.67 2.69 12.59 11.1 101.5 129.4
Table II
Results obtained for five species of arsenic in urinary CRM and an external quality assurance scheme
Arsenic species In-house spiked urine (10 mg/L)
% recovery (n ¼ 29)
Clinchek Level 1–923
(Cert As species mg/L)
Clinchek Level 2–923




Target Result Target Result Target Result Target Results
As3þ 9.0+ 0.8 (90%) 1.44–3.84 0.5+ 0.1 7.05–11.8 2.9+ 0.6 1.7–4.1 2.2 4.9–9.1 8.1
As5þ 9.3+ 0.9 (93%) 2.10–4.90 4.2+ 0.3 18.9–31.5 30.5+ 1.8 3.8–8.6 6.0 13.5–24.3 21.8
MMA 9.3+ 1.0 (93%) 1.50–3.50 2.8+ 0.5 5.03–8.38 7.2+ 0.5 1.0–2.8 1.7 6.8–11.6 10.9
DMA 9.3+ 1.1 (93%) 5.88–13.7 9.5+ 0.5 32.6–54.3 43.6+ 1.8 8.3–14.9 11.6 64.8–96 95.9
AB 9.3+ 1.8 (93%) 12.6–21.0 15.4+ 1.1 23.0–34.6 27.7+ 1.2 – – – –
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The results of the Bayesian model showed that there was no
significant dietary difference between females and males.
However, it did show a statistically significant difference
between gender for arsenic species AB and DMA only. The mean
urinary AB and DMA values for females were 77 and 28%
higher than males. In agreement with the nonparametric statis-
tical test, the Bayesian model found no significant difference
between smokers and nonsmokers; however, there were only 13
smokers (14% of the study group) in the dataset. As expected,
the consumption of fish resulted in increased urinary AB and
DMA concentrations. Volunteers who had eaten fish had urinary
DMA concentrations twice as high as that in those who had not
eaten fish and AB concentrations 10 times higher than that in
those who had not eaten fish. The Bayesian model also showed
that the mean concentration for urinary MMA was twice as high
for those who had consumed fish than that in those who had
not. However, the consumption of shellfish did not have an
effect on urinary MMA concentrations and showed only a 27%
increase in urinary DMA concentrations and a 2-fold increase in
urinary AB concentrations. Red wine also had a statistically sig-
nificant effect on urinary AB; the consumption of red wine was
found to increase AB concentrations by 79% even after adjusting
for consumption of fish and shellfish (of the 31 individuals who
had consumed red wine, nine had consumed neither fish nor
shellfish). Other dietary factors such as rice, mushrooms, real
ale, poultry, rice milk and bran were not found to be statistically
significant in the model for any of the four arsenic species.
To quantify and compare the variation of lognormally distribu-
ted measurements between the different arsenic species, the
geometric coefficient of variation (GCV) was determined. The






where s is the standard deviation of the data after a lognormal
transformation. The greater the GCV, the greater the variability
in the measurements. AB showed the greatest variability with a
GCV of 2.96, and DMA showed the lowest variability with a GCV
of 0.77. As3þ and MMA had a GCV of 1.38 and 0.80, respectively.
The correlation between species was determined by calculat-
ing Pearson’s correlation coefficient (a measure of the linear as-
sociation between two variables) for the natural logarithm of the
pairs of species. Nondetects were dealt with by imputation,
whereby their values were replaced with the corresponding
central estimates from the MCMC analysis, rather than by a
common fixed value. This ensured that the nondetects did not
introduce an artificial pattern to the data at low concentrations
that could potentially dominate the dataset (25). A strong posi-
tive correlation was found between MMA and DMA; a moderate
correlation was found between As3þ and MMA, As3þ and DMA,
MMA and AB as well as DMA and AB. A very weak correlation was
found between As3þ and AB. The correlation coefficient was not
calculated for As5þ due to the very high proportion (63%) of
measurements below the LOQ.
Discussion
Exposure to arsenic can occur through diet, environmental or
occupational sources. Reported here is the determined urinary
arsenic speciation concentrations collected from 95 volunteers
who are not occupationally exposed to arsenic. The median un-
corrected for creatinine (mg/L) concentrations for all the five
species of arsenic gave good agreement with other studies
where ‘control’ unexposed samples were reported and for back-
ground level studies (14, 15, 19, 21). Both the NHANES (14) and
HBECC (15) studies quantified DMA and AB only, due to the
large proportion of reported nondetects for As3þ, As5þ and
MMA. The LODs reported in the NHANES study were 1.2 mg/L
for As5þ, 1 mg/L for As3þ, 0.9 mg/L for MMA, 1.7 mg/L for DMA
and 0.4 mg/L for AB (26), and most of the 95th percentiles
reported in the HBECC study are marked as ‘use with caution’ or
‘unreliable to publish’ (15). It could be argued that both of these
arsenic speciation methods are not suitable for the analysis of
control samples. The LOD and LOQ values reported for this
novel arsenic speciation method demonstrated in this study are
lower and, therefore, better suited to the analysis of background
samples. The LOQs reported in both Heitland and Koster (18)
and Morton and Leese (20) could not achieve LOQ concentra-
tions of ,0.1 mg/L for any of the five species of arsenic, whereas
in this study the LOQ ranges from 0.02 to 0.04 mg/L. Despite dif-
fering LOD and LOQ, the 95th percentile uncorrected for
creatinine concentrations (mg/L) for all the arsenic species
apart from AB gave very good agreement with those reported by
both the NHANES (14) study for US unexposed residents
and Heitland and Koster (18) for German unexposed residents
(n ¼ 98). The median and the 95th percentile for creatinine-
uncorrected concentration (mg/L) for total inorganic arsenic
and methylated metabolites (not including AB in this study) are
3.1 and 15.1 mg/L, respectively, which are both lower than the
BEI (12) and BAT (13) values of 35 and 50 mg/L, respectively. In
this study, the 95th percentile concentration for AB gave a much
higher value of 126.7 mg/L (174.7 mmol/mol creatinine), com-
pared with 35.0 (13) and 22.7 mg/L (18) reported in other
studies. However, the HBECC (15) study gave a slightly higher
95th percentiles of 4.5 mg/L for As3þ and 30 mg/L for DMA, al-
though their reported value of 110 mg/L for AB is similar to that
obtained in our study. The predominant dietary species of
arsenic (AB) is found primarily in seafood, shellfish, algae and
seaweed products; however, it can also be found in poultry (5)
and cereal products such as rice and bran (6). AB is thought to
be the end point of arsenic metabolism in marine animals. It is
not, however, believed to be accumulative in humans, and fol-
lowing ingestion, AB is eliminated unchanged in urine, within a
couple of days. However, a study by Newcombe et al. (7)
reported that AB was present in the urine of volunteers after 12
days of an AB-free diet (no seafood or shellfish, chicken or mush-
rooms), however rice was consumed. Newcombe et al. (7) sug-
gested that dietary arsenic (AB) is present in rice. In our study,
11 urine samples had AB present, when no fish, seafood or
seaweed products had been eaten in the preceding 7 days, but
red wine, poultry and rice had been consumed. The median and
95th percentile concentrations for DMA in this study are 2.44
(4.30 mmol/mol creatinine) and 12.68 mg/L (16.08 mmol/mol
creatinine), respectively. The presence of methylated metabo-
lites in urine samples, which show no exposure to inorganic
arsenic, suggests that dietary sources are not only responsible
for the presence of AB in urine, but also DMA and to a lesser
extent MMA. Pearson et al., (8) also reported that methylated
metabolites can be from dietary sources, showing that excretion
of DMA in urine increased after eating American long-grain rice.
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Elevated DMA in urine after the consumption of different types
of fish has also been reported (4).
The regression model allowed us to investigate whether cre-
atinine correction to the uncorrected data is appropriate. The
results indicated that creatinine correction was effective for
each of the arsenic species, where regression modeling was
carried out (As3þ, MMA, DMA and AB).
Conclusion
The arsenic speciation method described in this paper has been
used to determine urinary arsenic speciation results in a cohort
of nonoccupationally exposed volunteers in the UK. This speci-
ation method demonstrates high sensitivity, enabling accurate
determinations of five species of arsenic in control urinary
samples. Despite this, 63% of samples had no As5þ present.
Statistical analysis indicated that creatinine correction was ef-
fective for each of the arsenic species, where regression modeling
was carried out (As3þ, MMA, DMA and AB). Fish consumption was
associated with higher levels of MMA, DMA and AB, shellfish with
higher levels of DMA and AB and red wine with higher levels of AB.
It can be expected that dietary sources of arsenic are not only
responsible for the presence of AB, but also for DMA and pos-
sibly MMA. The existence of methylated metabolites in a urine
sample does not necessarily equate to evidence of inorganic
arsenic exposure and its subsequent methylation. Therefore, a
method where an amalgamated value (total less AB) is deter-
mined is not an accurate measurement of exposure. To make an
inferred exposure assessment, a speciation result is required and
this could be further improved by keeping a diet log. There is a
need for a detailed characterization of arsenic content in food-
stuffs and beverages to make a more informed assessment. It
would also be useful to establish further occupational exposure
levels based on speciation results.
The results from this study mean that 95th percentile back-
ground reference ranges have been established for As3þ, As5þ,
MMA, DMA and AB. This will allow better interpretation of any
subsequent exposure.
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